What the business is, and whether it's a good one at a fair price.
Manufactures behind-the-ear (BTE) hearing aids and runs a remote audiology platform built around a patented diagnostic device called 'Omni', which sits at partner ENT clinics and links back to audiologists at the company's command centre for tests and fittings. Around 85–90% of revenue comes from own-manufactured products, with sales split across three channels — government (61% of FY26 revenue per the company's investor presentation), B2B, and a B2C Shop-in-Shop (SIS) clinic model in Tier 2/3 cities. Gross margins and average selling prices differ sharply by channel: 35–37% gross margin at Rs 1,700–2,800 ASP for government sales, 40–45% for B2B, and 65–70% at Rs 15,000 ASP for the SIS channel. Around 80 Omni installations are live today, with a stated target of 1,500 SIS clinics within three years, implying capex of about Rs 3 lakh per clinic and a gross outlay of roughly Rs 45 crore over the period. The company listed on BSE SME in October 2025 after raising Rs 44.7 crore through an IPO, has set up a wholly-owned US subsidiary (Earkart Inc.) and a 65% UK subsidiary (Earkart Health Limited), and is moving into pharmaceuticals with planned WOS for pharma manufacturing and healthcare services. The single largest cost is raw materials at 43.7% of revenue, followed by employee costs at 11.0% and other operating expenses at 12.6%.
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from EARKART LIMITED's filed financials and exchange disclosures
EARKART LIMITED is a Healthcare Equipment & Supplies company listed on BSE.
Not in the latest reported year — EARKART LIMITED's dividend payout for FY26 was nil.
Effectively yes. It holds ₹22 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, EARKART LIMITED ranks 9 of 17 in Medical Equipment & Supplies — cheaper than 50% of them, against an industry median of 20.0×. This is a position, not a valuation judgement.
On a typical session EARKART LIMITED moves 2.56% — that is the median absolute close-to-close move across its last 154 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by EARKART LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
